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Abstract
Previous reports have demonstrated that select cancers depend on BRD4 to regulate oncogenic 
gene transcriptional programs. Here, we describe a novel role for BRD4 in DNA damage response 
(DDR). BRD4 associates with and regulates the function of pre-replication factor CDC6 and plays 
an indispensable part in DNA replication checkpoint signaling. Inhibition of BRD4 by JQ1 or 
AZD5153 resulted in a rapid, time-dependent reduction in CHK1 phosphorylation and aberrant 
DNA replication re-initiation. Furthermore, BRD4 inhibition sensitized cancer cells to various 
replication stress-inducing agents, and synergized with ATR inhibitor AZD6738 to induce cell 
killing across a number of cancer cell lines. The synergistic interaction between AZD5153 and 
AZD6738 is translatable to in vivo ovarian cell-line and patient-derived xenograft models. Taken 
together, our study uncovers a new biological function of BRD4 and provides mechanistic 
rationale for combining BET inhibitors with DDR-targeted agents for cancer therapy.
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Introduction
During each round of cell cycle, 3×109 base pairs of genetic information needs to be 
precisely duplicated and distributed into daughter cells. Meanwhile, cells are constantly 
challenged by endogenous and exogenous insults that lead to errors during the DNA 
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replication process. Depletion of the nucleotide pool and disruption of chromatin structure 
can cause replication stress(1). In tumors, uncontrolled activation of oncogenes such as 
RAS, MYC, and CCNE1 can lead to increased transcription and DNA replication origin 
firing, which have also been linked to elevated replication stress(1, 2). Under conditions of 
replication stress, the Minichromosome maintenance (MCM) replicative helicase complex 
becomes uncoupled from the DNA replication machinery, and single-stranded DNA 
(ssDNA) is generated as a result of continuous DNA unwinding(1, 3). Unprotected ssDNA 
triggers the activation of the replication stress response, also known as the intra-S phase 
checkpoint response. In this process, the ATR-CHK1 signaling axis plays a prominent 
role(3, 4). Activation of CHK1 and its downstream effectors lead to an array of coordinated 
activities that include reduced new origin firing, delay of cell cycle progression, and 
restoration of the stalled replication forks(3). In contrast, a defective intra-S phase 
checkpoint allows DNA replication and cell cycle progression in the presence of stalled 
replication forks and damaged DNA. Persistent replication stress will lead to replication fork 
collapse, DNA strand breaks, chromosome mis-segregation and genome instability(2, 5).
BET (bromodomain and extraterminal domain) family proteins, BRD2, BRD3, BRD4 and 
BRDT, are a family of epigenetic readers that recognize acetylated-lysine residues on 
histones and non-histone chromatin factors(6, 7). BRD4, the best studied member of this 
family, has been implicated in various human cancers(8–11). To date, a majority of BRD4 
cancer dependency has been attributed to its role in regulating gene transcription through 
recruitment of transcription regulatory complexes, such as the general initiation cofactor 
Mediator and the Positive Transcription Elongation Factor b (pTEFb)(12–14). Recently, 
after the chemical feasibility of small molecule BET bromodomain inhibition was 
demonstrated, there has been intense interest in targeting BRD4 for cancer therapy. Several 
BET bromodomain inhibitors (BETi) capable of disrupting BET protein interactions with 
chromatin and other nuclear proteins have shown anti-tumor activity in a number of 
preclinical cancer models(6, 8). A subset of those BETi have demonstrated initial promising 
clinical activity in acute leukemia, lymphoma, and NUT midline carcinoma (NMC)(9, 15, 
16).
Here, we explored unidentified BRD4 functions and describe a novel role of BRD4 in DNA 
replication stress response. We show that BRD4 associates with the DNA pre-replication 
complex and regulates its activity. Blockade of BRD4 function with BETi or siRNA-
mediated BRD4 knockdown resulted in defective intra-S phase checkpoint signaling and 
sensitized cancer cells to both replication stress-inducing chemotherapy and a small 
molecule inhibitor of the ATR kinase, AZD6738.
Results
BRD4 associates with the DNA pre-replication complex and regulates DNA replication 
checkpoint signaling
To identify novel functions of BRD4, we examined BRD4-associated proteins under 
different growth conditions via immune-affinity purification and mass spectrometry (MS) 
analysis. 239 high-confidence protein targets that selectively interact with BRD4 compared 
to isotype control with Exponentially Modified Protein Abundance Index (emPAI) >0.1 were 
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identified in U2OS osteosarcoma cells (Table S1). These targets were further subjected to 
pathway and protein-complex based enrichment analysis (Figure 1A). Consistent with 
previous reports, proteins involved in regulating gene expression, cell cycle progression and 
mitosis were enriched (Figure 1A)(12, 13, 17, 18). Interestingly, several components of the 
DNA pre-replication complex, including CDC6, MCM5 and MCM7, were identified as 
high-confidence BRD4 interacting proteins (Figure 1B)(19). Among these pre-replication 
factors, CDC6 exhibited the most consistent and strongest interaction with BRD4 under all 
MS conditions evaluated (Table S1). We verified the association between BRD4 and CDC6, 
and similarly with another pre-replication complex member CDC7, by protein co-
immunoprecipitation followed by western blot analysis in U2OS cells and OVCAR3 ovarian 
cancer cells. The consistent interactions between BRD4 and CDC6 observed in different 
cancer cell lines and under different cell lysis conditions (Benzonase and sonication) suggest 
that this interaction is broadly relevant (Figure 1C, Figure S1A). However, the interaction 
between BRD4 and the DNA pre-replication complex is not likely mediated through the 
BRD4 bromodomains as the potent BET bromodomain inhibitor AZD5153 did not disrupt 
their interactions (Figure 1C)(8, 20, 21).
BRD4 plays a role in regulating DNA replication checkpoint signaling
During DNA replication initiation, CDC6 functions as a replication licensing factor by 
binding to the origin recognition complex (ORC) and facilitates the assembly of the DNA 
pre-replication complex and recruitment of the DNA replication machinery(22). 
Additionally, CDC6 serves an important role in the activation and maintenance of the intra-S 
phase replication checkpoint response(19, 22). Association of BRD4 with CDC6 prompted 
us to investigate whether BRD4 has a function in these processes. To examine whether 
BRD4 modulates the DNA replication checkpoint response, we utilized AZD5153 to 
abrogate the function of BRD4 BET bromodomains and hydroxyurea (HU) to induce 
exogenous DNA replication stress(23). In U2OS cells, treatment with HU led to strong 
CHK1 activation as evidenced by marked increase of CHK1 phosphorylation at Ser317 
(pCHK1 S317) (Figure 1D, left panel) as well as Ser345 (Figure S1B). Interestingly, the 
HU-induced CHK1 activation was significantly attenuated when cells were co-treated with 
AZD5153 over a time course of 2- to 6-hours, or when BRD4 protein expression was 
decreased by siRNA-mediated knockdown (Figure 1D, Figure S1B-C). The phosphorylation 
level of ATR (pATR T1989), an upstream kinase of CHK1 which senses RPA-coated single-
stranded DNA generated upon uncoupling of replisomes and DNA unwinding(24), was not 
altered by either HU treatment or HU in combination with AZD5153 (Figure 1D). However, 
due to the limitation with the commercially available pATR antibody, we can’t be certain if 
the kinase activity of ATR is influenced by AZD5153. We next tested in an in vitro kinase 
assay and confirmed that AZD5153 or JQ1, two BETi with distinct chemical structures, do 
not inhibit ATR kinase activity (Figure S1D). Furthermore, no detectable modulation was 
observed for phospho-ATM (S1981) or downstream phospho-CHK2 (T68) (Figure 1D), two 
key proteins involved in DDR signaling during ATM-dependent DNA double-strand break 
repair(25). The increase of pCHK1 level induced by HU and the dampened effect exerted by 
BRD4 bromodomain inhibition were observed without a concomitant change in total protein 
or mRNA levels of CHK1, ATR activators TopBP1 and Rad17, or other DNA replication and 
DNA damage response factors (Figure S1E-F), and were not recapitulated by treatment with 
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general gene transcriptional inhibitors Flavopiridol or Dinaciclib (Figure S1G)(26, 27), 
suggesting that this is independent of the transcription regulatory activity of BRD4.
To confirm this mechanism in an alternative cellular context, we evaluated the effect of BETi 
on pCHK1 levels in OVCAR3 ovarian cancer cells. OVCAR3 cells harbor CCNE1 
amplification and exhibit high endogenous replication stress leading to elevated basal 
pCHK1 signaling activity (Figure 1E)(28). When OVCAR3 cells were treated with JQ1 or 
AZD5153, we observed a time-dependent reduction of pCHK1 seen as early as 30 min post 
treatment, with a maximal decrease in pCHK1(~80% reduction by JQ1 and >95% by 
AZD5153) reached at 1h and maintained throughout the duration of the experiment (Figure 
1E). The modulation of pCHK1 by AZD5153 is also dose-dependent, with a potency that is 
comparable to the affinity of AZD5153 to BRD4 bromodomains (Figure 1F and Figure 
S1H). These findings demonstrate that BRD4 can regulate CHK1 signaling in response to 
both endogenous and exogenous DNA replication stress.
Inhibition of BRD4 leads to aberrant DNA replication re-initiation and sensitizes cells to 
replication stress-inducing agents
CHK1 activation following replication stress triggers an array of downstream signaling 
events, which lead to deceleration of ongoing replication, inhibition of new replication 
origin firing and recruitment of DNA repair machinery. In order to examine outcomes 
associated with defective intra-S phase checkpoint following BRD4 inhibition, we developed 
an imaging-based assay to monitor DNA replication activity in cultured cancer cells (Figure 
2A). This assay utilized the dual pulse labeling with two nucleotide analogs, 5-bromo-2’-
deoxyuridine (BrdU) and 5-Ethynyl-2’-deoxyuridine (EdU), to directly monitor the impact 
of BETi treatment on DNA replication activity following release from HU-induced DNA 
replication arrest. Consistent with expectations, DNA replication was completely blocked 
after HU treatment (Figure 2B, HU only). Four hours after HU was removed from the 
culture media, a baseline DNA replication activity, as indicated by EdU incorporation, 
resumed in DMSO-treated control cells (Figure 2B, DMSO). Remarkably, there was ~30% 
increase of EdU incorporation when cells were treated with JQ1 or AZD5153 (Figure 2B-
C), a level that is comparable to ATR inhibitor AZD6738 (Figure S2A)(29, 30). These 
results suggest that BETi-induced defective intra-S phase checkpoint signaling can give rise 
to hyper-activated DNA replication following replication stress, possibly due to aberrant 
restart of stalled replication forks or firing of dormant origins. Consistent with previous 
findings, we were unable to recapitulate the same enhanced DNA replication phenotype with 
general transcription inhibitors Flavopiridol or Dinaciclib (Figure S2B).
We next assessed whether reduced CHK1 signaling caused by BET inhibition led to 
defective downstream G2/M checkpoint and increased sensitivity to replication stress-
inducing agents. Indeed, cell treated with AZD5153 was able to circumvent the mitotic 
blockade under replication stress conditions induced by etoposide, similar to the effects 
exerted by an ATR kinase inhibitor (Figure S2C). Accumulation of DNA damage as 
indicated by γH2AX was measured by flow cytometry in U2OS cells treated with HU in the 
absence or presence of AZD5153. Continuous treatment of HU resulted in a time-dependent 
increase in the number of γH2AX positive cells (Figure 2D-E). When AZD5153 and HU 
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were added simultaneously, the number of γH2AX positive cells increased by more than 2 
fold compared to HU treatment alone (Figure 2D-E). Interestingly, when AZD5153 was 
combined with etoposide, another replication stress-inducing agent with a different mode of 
action(31), we observed enhanced cell killing in a five day cell viability experiment (Figure 
S2D). This observation is consistent with the notion that BRD4 inhibition leads to defective 
replication stress checkpoint, which exacerbates the cytotoxicity effect of a DNA replication 
stress-inducing agent. Together, these data further support a role of BRD4 in mediating a 
proficient DNA replication stress response and point to potential therapeutic applications of 
BET inhibitors in tumors with high intrinsic replication stress or when combined with agents 
that induce DNA replication stress.
Defective replication stress response induced by BRD4 inhibition is CDC6 dependent
Previous reports demonstrated that CDC6 is required for the activation of replication 
checkpoint response(22). Therefore, we aimed to determine whether the BETi-induced 
defective S-phase checkpoint response is dependent on CDC6. When CDC6 protein was 
depleted by siRNA in U2OS cells, we observed a marked decrease in HU-induced CHK1 
phosphorylation (Figure S3A). While there was a moderate decrease of the percentage of 
replicating cells and baseline DNA replication activity, CDC6 knockdowns clearly abrogated 
the enhanced DNA replication activity induced by BETi treatment, resulting in an EdU 
incorporation level that was comparable to DMSO control (Figure 3A, Figure S3B). To 
further establish that the role of BRD4 in intra-S phase checkpoint signaling is dependent on 
the CDC6 signaling pathway, two small molecule inhibitors XL413 and PHA767491, which 
target a CDC6 downstream effector kinase CDC7, were used in a set of analogous 
experiments (32, 33). We first confirmed the mechanism of action of these two compounds 
by monitoring the modulation of phospho-MCM2 S53 and S40/S41, two known CDC7 
phosphorylation sites, and lack of modulation of phospho-MCM S108, a non-CDC7 
phosphorylation site (Figure S3C). Consistently, CDC7 inhibition reduced baseline 
replication activity. CDC7 inhibitors treatment also abolished BETi-induced aberrant 
replication re-initiation, resulting in a reduction in DNA replication activity comparable to 
the effects seen with CDC6 protein knockdown (Figure 3B). Altogether, these data support 
that BET inhibitor treatment leads to aberrant DNA replication through a CDC6-dependent 
mechanism.
To further dissect the interplay between BRD4 and CDC6 signaling pathways, we examined 
the effect of BET inhibition on CDC6 function. During DNA replication licensing and pre-
replication complex assembly, CDC6 activity is tightly regulated by cyclin-dependent 
kinases (CDKs)-mediated phosphorylation in a cell cycle-dependent fashion. CDK2 
phosphorylates CDC6 at Ser54 during G1 phase, which serves as an activation signal to 
stimulate the recruitment of MCM complex and pre-replication complex assembly under 
normal growth conditions(34–36). This phosphorylation event has also been shown to 
regulate CDC6 localization and stability (36–38). Following a 2-hour AZD5153 treatment, 
we observed a significant increase in the percentage of cells stained positive for nuclear 
phospho-CDC6 (Ser54) foci, increasing from 33% in DMSO-treated group to 93% in 
AZD5153-treated group, and a ~14% increase in total nuclear phospho-CDC6 intensity 
(Figure 3C-D, Figure S3D). Cell cycle analysis revealed that AZD5153 treatment did not 
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alter cell cycle distribution, suggesting that changes in CDC6 phoshporylation is unlikely 
due to cell cycle blockade (Figure S3E). Next, we examined whether the increase in CDC6 
phosphorylation status affects its stability. We used cycloheximide to block new protein 
synthesis and monitored both phospho-CDC6 Ser54 and total CDC6 turnover after 
AZD5153 treatment. Consistent with previous observation, AZD5153 caused an increase in 
phospho-CDC6 levels (Figure 3E, t=0). Interestingly, phospho-CDC6, and to a lesser degree 
total CDC6, degraded at a faster rate in the presence of AZD5153 (Figure 3E). These 
observations suggested that AZD5153 treatment causes an accumulation of active CDC6 on 
chromatin to promote hyper-activated DNA replication activity. However, the alteration in 
CDC6 activity also triggers faster turnover of CDC6, possibly leading to defective intra S-
phase checkpoint signaling. Altogether, these data demonstrated that disruption of BRD4 
function with BET inhibitor impacts CDC6 activity, and that CDC6 and BRD4 are both 
required for proficient DNA replication stress signaling.
BRD4 regulates CHK1 activation and combined inhibition of BRD4 and ATR results in 
enhanced DNA damage and apoptosis
As a central signaling molecule during intra-S phase checkpoint activation, CHK1 is 
predominantly activated by the upstream kinase ATR. However, CHK1 can also be activated 
through ATR-independent pathways(39, 40). Under conditions where BETi attenuated 
CHK1 activation in response to replication stress, we could not determine whether cellular 
ATR activity was modulated by AZD5153 due to technical limitations, but we have 
confirmed that neither AZD5153 or JQ1 inhibits ATR kinase activity in vitro (Figure S1D). 
We further investigated the relationship between BETi-regulated CHK1 signaling and the 
ATR-CHK1 signaling axis by examining the effects of combined inhibition of ATR (with 
AZD6738) and BRD4 (with JQ1 or AZD5153) in OVCAR3 cells. Relatively low 
concentrations of AZD6738 or BETi (JQ1 or AZD5153) were chosen as each agent on its 
own only results in partial inhibition of pCHK1. When AZD6738 was combined with either 
JQ1 or AZD5153, near complete inhibition of pCHK1 was achieved (Figure 4A). This result 
suggests a specific mechanism where either BRD4 and ATR function in non-overlapping 
pathways in regulating CHK1 signaling activity, or BRD4 indirectly regulates ATR/CHK1 
signaling pathway through other regulatory components. Yet, a clearly combination benefit 
was seen with concurrent ATR kinase activity inhibition (with AZD6738) and BRD4 
inhibition.
We hypothesized that combination of BET and ATR inhibitors may lead to a compound 
defect in DNA replication checkpoint response and synergy in inducing DNA damage and 
cell death. To test this hypothesis, we assessed the DNA damage levels following co-
treatment with BRD4 and ATR inhibitors in OVCAR3 ovarian cancer cells. Consistent with 
their respective role in replication stress response signaling, single agent treatment with 
AZD5153 or AZD6738 caused an accumulation of DNA damage marker, γH2AX, in a 
time-dependent manner (Figure 4B-C). Notably, combination treatment of AZD5153 and 
AZD6738 caused an increase of accumulated γH2AX that is enriched in S-phase cells 
(Figure 4B-D). Moreover, the synergistic induction of DNA damage and apoptosis was 
observed across several cancer cell lines (Figure 4E). Next, we expanded our study to a 
cancer cell line panel consisting of 67 lines spanning five different cancer types. When we 
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examined the combination activity of AZD5153 and AZD6738 in this panel, we observed 
striking synergistic cell killing in a significant fraction of tested cell lines. However, when 
AZD5153 was combined with an ATM inhibitor (41), the synergy was largely absent (Figure 
4F, Table S2). These findings are consistent with the mechanistic interaction we depicted, 
and further reinforce the notion that there is specific mechanistic foundation for the 
combination benefit between BRD4 and ATR inhibitors.
Next we examined if the combination of BRD4 and ATR inhibition could be extended to the 
in vivo setting. AZD5153 and AZD6738 were administered either as single agent or in 
combination to OVCAR3 tumor-bearing mice. AZD5153 or AZD6738 single agent 
treatment, as well as co-administration of both drugs, were well tolerated, and no significant 
body weight loss was observed in treated animals (Figure 5A). After three weeks of dosing, 
co-administration of AZD5153 and AZD6738 significantly inhibited tumor growth relative 
to each single agent alone (tumor growth inhibition after 21 day dosing: AZD6738, 58%; 
AZD5153, 74%; combo, >100% TGI with 21% tumor regression, p<0.0001) (Figures 5A 
and S4A). Pharmacodynamics study revealed that increased levels of single-stranded DNA, 
DNA damage and apoptosis, indicated by phospho-RPA, γH2AX and cleaved-PARP 
respectively, were observed in tumor samples following repeated co-treatment with 
AZD5153 and AZD6738 (Figure 5B). To further evaluate the in vivo efficacy of combined 
inhibition of ATR and BRD4, we tested this concept in three ovarian patient-derived 
xenograft (PDX) models utilizing a mouse clinical trial format, where three tumor-bearing 
mice were included in the vehicle group to account for variability in tumor growth and a 
single tumor-bearing mouse was enrolled onto each treatment group. Compared to either 
single agent alone, the combination of AZD5153 and AZD6738 exhibited significantly 
stronger anti-tumor activity in two of the three PDX models (GTG-0258 and CTG-0486) 
(Figures 5C and S4B). These data suggest that, due to the parallel nature of ATR and BRD4 
in regulating CHK1 activation, combined inhibition of ATR and BRD4 can potentially 
afford greater anti-tumor efficacy in vivo by synergistically inducing DNA damage and 
apoptosis.
Discussion
In this study, we describe a novel function for the BET epigenetic reader protein, BRD4, in 
DNA damage response signaling. Specifically, we demonstrate that BRD4 is an important 
signaling molecule for intra-S phase replication checkpoint activation. Small molecule-
mediated inhibition and siRNA-mediated knockdown of BRD4 lead to defective CHK1 
activation in response to exogenous and endogenous replication stress. In contrast to the 
well-established role of BRD4 in transcription regulation, we provide evidence that BRD4 
regulates DNA damage response signaling in a transcriptionally-independent manner. First 
line of evidence that supports this statement is that defective CHK1 signaling was not 
accompanied by changes in the expression levels of key relevant signaling factors following 
BET inhibition. Secondly, the aberrant replication phenotype induced by AZD5153 
treatment cannot be recapitulated by pan-transcription inhibitors treatment. Mechanistic 
studies reveal that BRD4 modulates the activity of CDC6, a component of the DNA pre-
replication complex that has been implicated in replication stress response signaling. BETi 
treatment leads to activation and faster turnover of CDC6, and enhanced replication re-
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initiation following replication stress challenge. As a result, BETi treatment sensitizes cancer 
cells to replication stress-inducing agents such as HU or etoposide.
The prominent role of BRD4 in modulating replication stress response signaling could be 
envisaged, as dynamic epigenetic modifications at, or near, sites of DNA damage are crucial 
for proper initiation of DNA damage response signaling, particularly in the case of DNA 
double-strand break (DSB) repair(42). It has been estimated that over a third of human 
bromodomain containing proteins respond to DNA damage, either directly by locating to 
DNA damage sites or indirectly by affecting chromatin structures near damage sites(43). 
Previous studies showed that BRD4 associates with chromatin near replication forks, BRD4 
can function as a repair complex adaptor in nonhomologous end joining, and can also 
suppress DNA double strand break signaling by regulating chromatin condensation(18, 44, 
45). We hypothesize that BRD4-chromatin association is required for maintaining an 
unperturbed replication stress response signaling. Although AZD5153 treatment had no 
impact on the interaction between CDC6 and BRD4, we suspect that BRD4 displacement 
from chromatin may perturb the recruitment or redistribution of regulatory factors in 
response to replication stress, resulting in the immobilization of CDC6 to specific chromatin 
locations and its activation and turnover. Future studies warrant a more detailed mechanistic 
evaluation of how BRD4 recognizes chromatin near stalled replication forks and how BRD4 
regulates CDC6 activation.
Targeting the DDR pathways is a promising therapeutic strategy in treating cancers that are 
defective in one or more of the DDR pathways or show increased dependency on DDR due 
to elevated DNA damage levels(46, 47). One good example is the recent approval of olaparib 
(Lynparza™), a poly ADP-ribose polymerase (PARP) inhibitor, in treating ovarian cancers 
which harbor BRCA1 or BRCA2 mutations(48, 49). In a similar fashion, ATR and CHK1 
inhibitors have been shown to cause selective cytotoxic effects in cancer cells over-
expressing CCNE1, due to their increased dependency on ATR/CHK1 signaling to cope with 
CyclinE1-induced replication stress(50). Interestingly, BRD4 is focally amplified in ~18% 
HGSOC samples (TCGA), and often is co-amplified with CCNE1 as they are both located 
near the centromere of chromosome 19. These copy-number alterations are also mutually-
exclusive with BRCA1 and BRCA2 loss-of-function mutations(51). We showed that BRD4 
regulates CHK1 activation through a mechanism that is likely to be independent of ATR 
signaling, and concurrent treatment with BETi and ATRi leads to a more profound inhibition 
of CHK1 activity, increase of DNA damage, and enhanced anti-cancer effects in a range of 
in vitro and in vivo models. These findings demonstrate promise of BRD4-targeted agents as 
a therapeutic option in ovarian cancers, particularly in the non-BRCA1/2 mutant population 
that exhibit high replication stress. Further investigation is needed to explore the 
combination of BETi with other DDR-targeted agents in treating cancer types that exhibit 
specific DDR dependencies.
In conclusion, we uncovered a key role of BRD4 in mediating replication stress response 
signaling and expanded our understanding of the physiological functions of BET proteins. 
Combining BETi with specific DDR-targeted agents may offer superior efficacy in tumors 
with high replication stress or those exhibiting increased dependency on CHK1-mediated 
checkpoint activity. Together with previously described role of BRD4 in transcription 
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regulation, we propose that BET inhibitors may exert anti-tumor effects through multiple 
mechanisms, i.e. preventing transcription of key oncogenic programs and exacerbating 
replication stress responses.
Material and Methods
Cells and reagents:
U2OS and OVCAR3 cells were purchased from ATCC. Antibodies used for Western Blot 
analysis were from Cell Signaling (Danvers, MA, USA): CDC6 (CS3387), CDK9 (CS2316), 
phospho-CHK1 Ser317 (CS12302), phospho-CHK1 Ser345 (CS2348), CHK1 (CS2360), 
phospho-CHK2 Thr68 (CS2197), CHK2 (CS6334), ATR (CS2790), ATRIP (CS2737), 
Claspin (CS2800), Germinin (CS5165), phospho-ATM Ser1981 (CS5883), CDT1 (CS8064), 
cleaved caspase 3 Asp175 (CS9661), MRE11 (CS4847), NBS1 (CS14956), Rad17 
(CS8561), TOPBP1 (CS14342), MCM2 (CS3619), cleaved-PARP Asp214 (CS5625), RPA 
(CS2208), GAPDH (CS5174), Histone H3 (CS4499); from Bethyl Laboratories 
(Montgomery, TX, USA): CDC7 (A302–504A), phospho-RPA32 S4/S8 (A300–245A), 
phospho-RPA32 S33 (A300246A), phospho-MCM2 S108 (A300–094A), phospho-MCM2 
S53 (A300–756A), phospho-MCM2 S40/41 (A300–788A); from Millipore: phospho-
Histone H2A.X Ser139 (05–636); from Abcam (Cambridge, MA, USA): BRD4 (ab128874), 
phospho-CDC6 Ser54 (ab75809), ETAA1 (ab197017); from Genetex (Irvine, CA, USA): 
phospho ATR-Thr1989 (GTX128145); from Sigma (St. Louis, MO, USA): vinculin 
(V9264); and from Covance (Dedham, MA, USA): Phospho-RNA Pol II Ser2 
(#MMS-129R). Reagents were purchased from Sigma (St. Louis, MO, USA): Hydroxyurea 
(H8627), BrdU (B5002); from Selleckchem: JQ1 (S7110), Flavopiridol (S1230), Dinaciclib 
(S2768), etoposide (S1225), XL413 (S7547), PHA-767491 (S2742). AZD5153, AZD6738 
and ATM inhibitor compound 72 were developed by AstraZeneca.
Western Blot analysis:
After treatment, cells were lysed in cell lysis buffer (25mM Tris7.4, 300mM NaCl, 1mM 
EDTA, 1% Triton) supplemented with protease and phosphatase inhibitor cocktail (Cell 
Signaling #5872). For xenograft tumor samples, tissues were homogenized in SDS lysis 
buffer (100mM Tris-HCl buffer, pH7.4, 10% Glycerol and 1% SDS) supplemented with 
protease and phosphatase inhibitor cocktail. 4μg of lysates were loaded for immunoblotting 
following standard procedures. For protein halflife studies, U2OS cells were first treated 
with DMSO or AZD5153 for 30 minutes before addition of 10 μg/ml of cycloheximide (Cell 
Signaling #2112). Cell extracts were collected after various amounts of time, and the 
expression levels of proteins of interest were examined by western blot analysis following 
standard procedure.
Immunofluorescence:
After AZD5153 treatment, U2OS cells were pre-extracted with 0.5% triton in PBS for 5 min 
before being fixed with 4% paraformaldehyde for 15 min at room temperature. Cells were 
then blocked with 5% BSA in PBST followed by primary antibody (Phospho-CDC6 S54, 
Abcam # ab75809, 1:500) and secondary antibody (Alexa Fluor 488 conjugate) staining. 
DAPI was used to counter stain DNA. Image acquisition was carried out on ImageXpress 
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MicroXL High Content Screening System (Molecular Devices, Sunnyvale, CA, USA). The 
number of phospho-CDC6 foci in the nuclei was scored and quantified using MetaXpress 
Software (Molecular Devices). An average of 500 nuclei were analyzed for each 
experimental condition. Results shown represent average of three independent experiments.
Replication re-initiation/restart assay and quantification:
U2OS cells were first pulse-labeled with 10μM BrdU for 30 min followed by 2X PBS wash 
and then treated with 2mM HU in growth medium for 1 hour. Next, cells were washed twice 
with PBS and replenished with fresh growth media containing different inhibitors. After a 4h 
recovery in fresh media with the presence of different inhibitors, cells were pulse-labeled 
with 10μM EdU for 30 min before being fixed for staining. For BrdU and EdU staining, 
cells were fixed with 4% paraformaldehyde for 15 min at RT. After 2X PBS wash, DNA 
were denatured with 2N HCl in PBS for 20 min at RT followed by 2X wash with PBS. Cell 
were then permeabilized with 0.5% Triton in PBS for 5 min at RT and blocked with 5% 
BSA in PBST for 30 min at RT. Click-iT® Plus EdU Alexa Fluor® 647 Imaging Kit 
(#C10340, Thermo Fisher Scientific, Waltham, MA, USA) was used to stain EdU following 
manufacturer’s protocol. After EdU staining, cells were incubated with anti-BrdU antibody 
(Cell Signaling #CS5292, 1:500) for 3h at RT before secondary antibody (Alexa Fluor 488 
conjugate) and DAPI staining. Image acquisition was carried out on ImageXpress MicroXL 
High Content Screening System (Molecular Devices). EdU intensity was scored in BrdU 
positive cells and data analysis was performed with MetaXpress Software (Molecular 
Devices). Results shown represent average of three independent experiments. Statistical 
significance was evaluated using two-tailed t test.
Flow cytometry and cell cycle analysis:
For cell cycle analysis, treated cells were labeled with 10μM EdU for 1 hour before being 
fixed and stained for EdU and DNA content using Click-iT™ Plus EdU Alexa Fluor™ 647 
Flow Cytometry Assay Kit (C10634, Thermo Fisher Scientific, Waltham, MA) following 
manufacturer’s instructions. For measuring cellular γH2AX levels, treated cells were 
trypsinized from cell culture plates and fixed with 4% paraformaldehyde. 1×106 cells were 
washed once with 1 % BSA-PBS and permeabilized with 0.2% Trition in PBS for 15 
minutes at RT. FITC-conjugated γH2AX antibody (#06–202A, Millipore, Bellerica, MA, 
USA) was added to cells and allowed to stain for 1 hour at RT in the dark. Cells were then 
washed once with 1 % BSA-PBS and resuspended in 200 μl PBS containing DAPI (final 
concentration 1μg/μl). After 30 min incubation in the dark, samples were analyzed on a 
LSRFortessa cytometer (BD, San Jose, CA, USA). For G2/M checkpoint analysis, PE-
conjugated phospho-Histone H3 Ser10 antibody (#5764, Cell Signaling) was used to stain 
havested cells after 24 hour treatment with 10μM Etoposide following the same staining 
procedure. Data analysis was done with FlowJo V7.0. For each experiment, 150,000 events 
were captured and analyzed. Results shown represent average of three independent 
experiments.
Immunoprecipitation, Mass Spec and data analysis
For immunoprecipitation, 5×106 U2OS cells were resuspended in lysis buffer (50mM Tris 
7.4, 150mM NaCl, 1mM EDTA, 0.5% NP-40) supplemented with protease and phosphatase 
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inhibitors. Cell lysates were then processed in two different ways. For benzonase treatment, 
25 U/ml final concentration of benzonase (E1014, Sigma) was added to the lysates and 
incubated on ice for 30 minutes to digest chromatins. For benzonase-free lysis condition, 
cell lysates were then sonicated on a bioruptor (Diagenode, Denville, NJ, USA) for 6 cycles 
(30s on, 60s off) on medium setting. After sonication or benzonase treatment, cell lysates 
were cleared by centrifugation and then pre-cleared with protein A magnetic beads (Life 
Technologies #10002D). BRD4 antibody (Abcam #128874) was conjugated to protein A 
magnetic beads using 2mM BS reagent (Thermo Fisher #21585) in conjugation buffer 
(30mM Sodium Phosphate, 0.15M NaCl) for 30 min at RT. Conjugation reaction was 
stopped by quenching the reaction with 1M Tris HCl (PH 7.5, 50mM final concentration). 
Pre-cleared lysates and BRD4 antibody-conjugated protein A beads were then incubated 
together at 4 °C overnight with agitation. The next day, beads were washed 4 times with 
lysis buffer before sample buffer was added to elute the immuno-complexes.
For Mass Spec analysis, 2×107 U2OS cells were used for BRD4 pull-down following the 
same immunoprecipitation protocol. After overnight incubation, beads were washed 2X with 
lysis buffer, 2X with PBST and 2X with PBS. Washed beads were then resuspended in 50 μl 
8M Urea/300mM NH4HCO3. 5 μL 45mM DTT was added to each sample followed by 
incubation at 37 °C for 30 min with shaking. After the reaction mix cooled down to RT, 5 μl 
100mM Iodozcetamide was added and incubated for 30 min at RT in the dark. Next, the 
volume of beads mixture was brought up to 200 μl with water for overnight trypsin 
digestion. Trypsin (0.5 μg/μl working concentration) was added and the reaction mixture 
was incubated overnight at 37 °C with shaking. The next day, solution digests were desalted 
with C18 columns (ThermoFisher #89873) following standard protocols. Elution was 
vacuum dried and frozen down. Mass Spectrometry analysis was performed by the 
proteomics facility at the Keck Biotechnology Resource Laboratory at Yale University 
(http://medicine.yale.edu/keck/proteomics/index.aspx). Mascot software was used to identify 
proteins from LC-MS/MS data against the Swiss-Prot human database using a 1% false 
discovery rate (FDR).
Cell viability assay and combination screening:
For cancer cell line panel screening, detailed experimental procedure and data analysis have 
been previously described(52). Briefly, optimal 384-well seeding densities were pre-
determined for linear growth over 5 days. Cell suspension (30 μl per well) was seeded into 
384-well plates. Cells were allowed to grow overnight, and then treated with increasing 
concentrations of compounds in a 6×6 dosing matrix using Echo automatic dosing (Labcyte, 
San Jose, CA). After 5 days of growth, cell viability was measured using using an Alamar 
Blue (Invitrogen #DAL1100) or Sytox Green (Invitrogen S7020) endpoint following 
manufacturer’s protocol. Pre-dose measurements were made to indicate the number of live 
cells at the start of the experiment and thus an indication of whether the treatment regimen 
had resulted in cell death. The data are presented as % growth using the NCI formulas as 
follows: [(Ti-Tz)/(C-Tz)] ×100 for values for which Ti≥Tz, and [(Ti-Tz)/Tz] ×100 for 
concentrations for which Ti<Tz ( Tz represents the number of live cells at time zero, C 
represents the control growth and Ti represents the number of live cells in the presence of 
each drug regimen). This formula gives a growth percentage from −100% to +100%. 
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Negative scores are for cell killing and positive scores are for anti-proliferation. Experiments 
were performed in triplicate.
Two dimensional dose response matrix and curve fitting were processed in the combination 
extension of Genedata Screener12™ (Genedata, Basel, Switzerland). To enable this, % 
growth values were converted to a positive scale using a modified NCI formula as follows: 
[1-(Ti-Tz)/(C-Tz)] ×100 for values for which Ti≥Tz, and [1-(Ti-Tz)/Tz] ×100 for 
concentrations for which Ti<Tz. This gave a scale of 0–200% growth inhibition where 0–
100% is for anti-proliferation and 100–200% is for cell killing. Combination activity 
(synergism) was calculated using the Loewe dose-additivity model as previously described 
(53). This model of additivity provides a null-reference that is predicted by the expected 
response if the two agents were the same drug. The 3-dimensional model surface, predicted 
from the two single-agent response curves, is subtracted from the experimentally-derived 3-
dimensional dose effect surface to generate a difference volume. This excess matrix volume 
can be integrated to generate a synergy score.
Quantitative PCR:
Taqman Gene Expression assays were purchased from ThermoFisher Scientific (Waltham, 
MA, USA): ATR (Hs00992123_m1), ATRIP (Hs04335019_s1), CDC6 (HS00154374_m1), 
CDT1 (Hs00925491_g1), CHEK1/CHK1 (Hs00967506_m1), CHEK2/CHK2 
(Hs00200485_m1), CLSPN/Claspin (Hs00898637_m1), ETAA1(Hs00936568_m1), 
GMNN/Geminin (Hs00992846_m1), MRE11A (Hs00967437_m1), NBN/
NBS1(Hs01039845_m1), RAD17 (Hs00607830_m1), RPA2 (Hs00989573_g1), TOPBP1 
(Hs00199775_m1), GAPDH (Hs02786624_g1). qPCR reactions were carried out on a 7500 
HT instrument (Applied biosystems, Foster City, CA, USA). The amplified transcript level 
of each specific gene was normalized to that of GAPDH. Results shown represent average of 
three independent experiments.
In vivo Efficacy and Pharmacodynamics (PD) Studies
Female C.B.−17 scid mice were purchased from Charles River Laboratories (Wilmington, 
MA). Mice were housed under pathogen-free conditions in individual ventilated cages (IVC) 
at our AAALAC (Association for the Assessment and Accreditation of Laboratory Animal 
Care) accredited facility in Waltham, MA. All animal manipulations were conducted in a 
biosafety cabinet maintained under positive pressure. Mice used were 5–6 weeks old at the 
time of tumor implantation. All animal studies were conducted in accordance with the 
guidelines established by the internal IACUC (Institutional Animal Care and Use 
Committee) and reported following the ARRIVE (Animal Research: Reporting In Vivo 
experiments) guidelines(54).
2×107 OVCAR3 tumor cells were injected subcutaneously in the right flank of the mice. 
Tumor volumes (measured by caliper), animal body weight, and tumor condition were 
recorded twice weekly for the duration of the study. The tumor volume was calculated 
(taking length to be the longest diameter across the tumor and width to be the corresponding 
perpendicular diameter) using the formula: length (mm) × width (mm)2/0.52. For efficacy 
studies, tumor growth inhibition (TGI) was calculated as (RTVcontrol − RTVtreatment)*100)/
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(RTVcontrol − 1), where RTVcontrol is the geometric mean of relative tumor volume of 
control group and RTVtreatment is the treatment group. Data were log transformed to remove 
any size dependency before statistical evaluation. Statistical significance was evaluated using 
a one-tailed, 2-sample t test. For all studies, mice were randomized based on tumor volumes 
using stratified sampling and enrolled into control and treatment groups. For efficacy 
studies, dosing began when mean tumor size reached approximately 125 mm3and for PD 
studies the average tumor volume at the time of dosing was 400 mm3. Tumor samples for 
PD analysis were collected after four days of dosing.
PDX model screening was performed at Champions Oncology. Tumor fragments (2 mm3) 
were implanted into the left flank of female mice (Nu/Nu, Harlan). Once the tumor volume 
reached an average of 200 mm3, tumor volume was measured and mice were randomized 
into groups based on tumor volume. AZD5153, AZD6738 or the combination of the two 
drugs were dosed for 28 days and tumor volume and body weight were measured throughout 
the treatment period. Tumor growth inhibition was calculated based on changes in tumor 
volume on the last day that vehicle animals were available.
siRNA-mediated protein knockdown
Where indicated, cells were transfected with 25 pmol siRNA against CDC6 (Dharmacon 
J-003233–10, J-003233–12, J-003233–13, or L-003233 (pooled)), against BRD4 
(Dharmacon J004937–06, J004937–07, J004937–08), or siRNA negative control (Invitrogen 
AM4611) using Lipofectamine RNAiMAX (Invitrogen 13778075) according to the 
manufacturer’s instructions. Two days after siRNA transfection, cells were treated with HU 
for different periods of time and harvested for western blot analysis. For DNA replication re-
initiation/restart assay, siRNA-transfected cells were split into 96-well plates one day after 
siRNA transfection for subsequent labeling and imaging analysis.
In vitro ATR kinase assay
In vitro ATR kinase assay was perforem by Eurofins Pharma Discovery Services (Dundee, 
UK). Briefly, ATR/ATRIP (human) is incubated in assay buffer containing 50 nM GST-
cMyc-p53 and various concentrations of compounds. The reaction is initiated by the 
addition of the Mg/ATP (10 μM) mix. After incubation for 30 minutes at room temperature, 
the reaction is stopped by the addition of stop solution containing EDTA. Finally, detection 
buffer is added, which contains d2-labelled anti-GST monoclonal antibody, and a Europium-
labelled anti-phospho Ser15 antibody against phosphorylated p53. The plate is then read in 
time-resolved fluorescence mode and the homogeneous time-resolved fluorescence (HTRF) 
signal is determined according to the formula HTRF = 10000 × (Em665nm/Em620nm). 
Results shown represent average of three independent experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. BRD4 interacts with the pre-replication complex and regulates DNA replication 
checkpoint response.
A. Pathway enrichment analysis of BRD4 interacting proteins identified in 
immunoprecipitation and mass spectrometry analysis from U2OS cells (Database: 
ConsensusPathDB).
B. Identified pre-replication complex components that interacted with BRD4 and their 
corresponding emPAI scores. Only proteins with emPAI score >0.1 are listed. Also listed are 
CDK9, a component of the pTEFb complex and a known BRD4-interacting protein, and the 
bait protein BRD4.
C. Immunoprecipitations of BRD4 or IgG control were performed in U2OS and OVCAR3 
cells treated with or without AZD5153 (500 nM, 2h treatment). Western blot analysis of the 
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resulting immuno-complexes confirms association between BRD4 and the pre-replication 
complex.
D. Western Blot analysis showing time-dependent responses of phospho- and total CHK1, 
phospho- and total ATR, phospho-ATM, and phospho-CHK2 under replication stress 
conditions induced by hydroxyurea (HU, 10 mM) with or without the presence of AZD5153 
(500 nM) in U2OS cells. Bar plots on the right depict the relative pCHK1 intensity induced 
by HU over time and the dampened pCHK1 activity with AZD5153 treatment.
E. Western Blot analysis of ATR and CHK1 signaling activities in OVCAR3 cells following 
treatment with JQ1 (2 μM) or AZD5153 (500 nM) for indicated periods of time.
F: Western Blot analysis of OVCAR3 cells treated with increasing concentrations of 
AZD5153 (2 hour treatment).
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Figure 2. Inhibition of BRD4 leads to aberrant DNA replication re-initiation and sensitization to 
replication stress-inducing agents.
A. Schematic of DNA replication re-initiation/restart assay. U2OS cells are first pulse-
labeled with BrdU to identify cells in replication phase (S phase), and then treated with HU 
to induce replication stress. After one hour of HU treatment, HU is removed and cells are 
replenished with fresh medium with or without BETi (JQ1 or AZD5153). New DNA 
replication is detected with EdU pulse labeling after a 4-hour recovery.
B. Representative images of U2OS in replication re-initiating/restart assays. All cell nuclei 
are identified with DAPI staining. BrdU labels cells that are in S phase, whereas EdU 
staining indicates recovered DNA replication activity after HU treatment in these cells. In 
cells labeled as HU only, HU was not washed-out. Representative images of HU-, DMSO- 
and JQ1-treated samples are shown.
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C. Average EdU intensity (per cell) in BrdU positive cells indicates DNA replication re-
initiation under various experimental conditions (same as B, JQ1 2 μM, AZD5153 500 nM). 
All results are normalized to DMSO-treated control group (**** p<0.0001).
D. Pseudocolor plots of U2OS treated with HU or HU+AZD5153 analyzed by flow 
cytometry. γH2AX positive gate (outlined area) is determined based on unstained controls. 
γH2AX positive cells under each treatment condition are highlighted in gray. (HU 2 mM, 
AZD5153 500 nM, representative images are shown)
E. Quantification for percentage of γH2AX positive population in U2OS cells treated with 
HU without or with AZD5153 for increasing amounts of time (same as D, N=3).
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Figure 3. BETi leads to defective replication stress response through deregulated CDC6 activity.
A. Quantification of relative EdU incorporation in U2OS cells transfected with control 
siRNA or a pool of four different CDC6 siRNA as measured in the DNA replication re-
initiation/restart assay with or without AZD5153 treatment. (** p=0.0055)
B. Effects of two CDC7 inhibitors, XL413 (5 μM) and PHA767491 (5 μM), on DNA 
replication re-initiation/restart after HU treatment in the presence or absence of AZD5153.
C. Representative images of U2OS cells stained for phospho-CDC6 (S54) with or without 2-
hour AZD5153 treatment (500 nM). Selective regions are zoomed in to show phospho-
CDC6 foci.
D. Quantification of C for percentage of U2OS cells stained positive for phospho-CDC6 
(S54) foci following a 2-hour AZD5153 treatment.
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E. U2OS cells were treated with DMSO or AZD5153 (500nM) followed by cycloheximide 
chase to examine protein turnover rate. Expression levels of phospho-CDC6 Ser54 and total 
CDC6 at different time points following cycloheximide chase were examined by western 
blot. Quantification of phospho-CDC6 Ser54 and total CDC6 levels was graphed at the 
bottom (N=3).
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Figure 4. BETi and ATRi induce DNA damage and apoptosis in a synergistic manner.
A. Western Blot analysis of U2OS cells treated with BETi (JQ1 or AZD5153), ATRi 
(AZD6738), or combination of BETi and ATRi. Greater inhibition of phospho-CHK1 is seen 
with combination treatment compared to either single agent treatment alone. (AZD5153 250 
nM, JQ1 2 μM, AZD6738 100 nM, 24h treatment)
B. OVCAR3 cells were treated with BETi (AZD5153, 500nM), ATRi (AZD6738, 500 nM) 
or combination of AZD5153 and AZD6738 for indicated periods of time before being fixed 
and stained for γH2AX for flow cytometry analysis. Percentage of cells showing positive 
γH2AX staining at different time points are graphed (N=3).
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C. Pseudocolor plots showing γH2AX positive population after 24 hours of indicated 
treatment conditions (Same as B). γH2AX positive gate (outlined area) is determined based 
on unstained controls. γH2AX positive population are highlighted in grey.
D. Pseudocolor plots showing DNA content (x-axis) and γH2AX intensity (y-axis) 
distribution of OVCAR3 cells following a 24-hour treatment of indicated agents (Same as 
C). Note accumulation of γH2AX positive population between 2N and 4N DNA content 
(highlighted in red), indicating accumulated DNA damage in S phase cells.
E. Western Blot analysis of U2OS, OVCAR3 and OVCAR4 cells after treatment with 
AZD5153, AZD6738, or AZD5153+AZD6738 combo (AZD5153 500 nM, AZD6738 500 
nM, 24h treatment). γH2AX and cleaved-caspase 3 are used as makers for DNA damage 
and apoptosis, respectively.
F. Combination testing was performed in a panel of breast, small cell lung, non-small cell 
lung, ovarian, and gastric cancer cell lines. Cell viability was measured after combination 
treatment of AZD5153 with ATR inhibitor AZD6738 (67 cell lines), or with ATM inhibitor 
(Compound 72) (40 cell lines). Combination synergy scores were calculated using Loewe’s 
Model and the results are graphed as scatter plots showing the distribution of cell lines 
according to their synergy scores. Positive synergy score indicates greater than additive 
effects of two compounds in cell killing. Dashed line marks the synergy score of zero.
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Figure 5. Concurrent BET and ATR inhibition inhibits ovarian tumor growth in vivo.
A. OVCAR3 cells were injected subcutaneously into C.B.−17 scid mice and allowed to grow 
for 6 days. Tumor-bearing mice randomized into the following treatment groups (n = 10/
group) were orally administered vehicle once daily, 2.5 mg/kg AZD5153 once daily, 25 
mg/kg AZD6738 once daily, or a combination of AZD5153 and AZD6738 once daily for 21 
days. Data values for tumor volumes are represented as geometric mean ± SEM. Data values 
for % body weight change are represented as mean ± SEM of each treatment group.
B. Western blot analysis of indicated markers in OVCAR3 xenograft tumor samples after 
four repeated doses.
C. Bar graphs representing tumor volume change in N=1 testing of ovarian PDX models. 
For each model, tumor-bearing mice were randomized into each treatment group and were 
orally administered vehicle once daily (n = 3), 2.5 mg/kg AZD5153 once daily (n = 1), 25 
mg/kg AZD6738 once daily (n = 1), or a combination of AZD5153 and AZD6738 once 
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daily (n = 1) for 28 days. At the end of the treatment period, tumor volume was measured 
and % change in tumor volume was calculated.
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